报价延迟最少15分钟:2026/04/27 19:47 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
327.98 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
4.52/6.10
|
|
企业价值
13.15B
|
| 资产负债 |
|
每股账面净值
36.38
|
| 现金流量 |
|
现金流量率
0.02
|
| 损益表 |
|
收益
1.40B
|
|
每股收益
25.36
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products inthe United States, followed by international markets. |
